Key Trends and Insights into the Denosumab Market: Growth Rate and Opportunities to 2034
Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!
How has the denosumab market grown over the years?
The market size for denosumab has quickly expanded in the last few years. It is set to increase from $3.27 billion in 2024 to $3.7 billion in 2025, marking a compound annual growth rate (CAGR) of 13.1%. The substantial growth seen in the historic period is owing to progress in clinical trials and research, regulatory achievements and FDA approvals, heightened awareness about bone health, along with strategic alliances and marketing efforts.
What Is the forecasted market size and growth rate for the denosumab market?
In the coming years, the market size for denosumab is anticipated to experience significant growth. The expected market value will be approximately $5.59 billion in 2029, showcasing a compound annual growth rate (CAGR) of 10.9%. The expected growth during the forecast period can be attributed to factors like the increasing prevalence of bone metastases, advancement in cancer therapies, and osteoporosis, increasing osteoporosis awareness, new indications’ regulatory approval, and more. In the forecast period, key trends will be strategic alliances and partnerships, digital health solutions integration, extended indications and clinical applications, and advancements in biosimilar development.
Get your denosumab market report here!
https://www.thebusinessresearchcompany.com/report/denosumab-global-market-report
What are the major factors driving growth in the denosumab market?
The escalating incidence of osteoporosis is anticipated to spur the expansion of the denosumab market. Osteoporosis, a health disorder characterized by weakening of bones that leads to decreased bone density and elevated fracture risks, is addressed using denosumab which inhibits bone resorption by targeting the RANK ligand. For instance, statistics from the National Center for Biotechnology Information, a US government agency, revealed in September 2023 that data from the Canadian Longitudinal Study on Aging indicates physician-diagnosed osteoporosis had a prevalence of 12.7% and DXA-confirmed osteoporosis was at 5.9% among older adults living in communities, in females. Furthermore, a cross-sectional research conducted by Buttros and his team found a 24.6% prevalence of osteoporosis in postmenopausal women aged between 40 and 75, ascertained through bone mineral density (BMD) measurements. Consequently, the surging incidence of osteoporosis is stimulating the expansion of the denosumab market.
What key areas define the segmentation of the global denosumab Market?
The denosumab market covered in this report is segmented –
1) By Drug Classification: Prolia, Xgeva, Others
2) By Type: 60 mg, 120 mg
3) By End-Users: Hospitals, Homecare, Specialty Clinics, Ambulatory Surgical Centers
Get your free sample now – explore exclusive market insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13835&type=smp
What are the top market players propelling the growth of the denosumab industry?
Major companies operating in the denosumab market report are Johnson & Johnson, F. Hoffmann-La Roche Ltd., Novartis International AG, Sanofi SA, GlaxoSmithKline plc, Eli Lilly and Company, Amgen Inc., Asahi Kasei Corporation, Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Daiichi Sankyo Company, Limited, Mylan N.V., Sandoz International GmbH, Daiichi Sankyo Company Limited, Aurobindo Pharma Limited, Cipla Limited, Dr. Reddy’s Laboratories Ltd., Hikma Pharmaceuticals PLC, Celltrion Inc., Amneal Pharmaceuticals Inc, Cadila Healthcare Limited, Lupin Limited, Biocon Limited, Torrent Pharmaceuticals Ltd., Jubilant Life Sciences Limited, Ajanta Pharma Limited
What are the key trends shaping the future of the denosumab market?
Major enterprises active in the denosumab market are placing a heightened emphasis on pioneering new solutions, such as introducing primary treatments for osteoporosis, to gain an upper hand in the market. The initial or main therapeutic method suggested by healthcare experts for managing diagnosed osteoporosis patients is what is referred to as first-line treatment for osteoporosis. For instance, Boan Biotech, a biotech firm in China, got the green light from China’s National Medical Products Administration (NMPA) for its denosumab biosimilar, Boyoubei, in November 2022. This made it the first Chinese firm to create a denosumab injection. Efforts are underway to make it available in markets beyond China’s borders, including Europe and the US, with global marketing aims. The drug is endorsed as a primary osteoporosis treatment in various care guidelines. The medicine holds promise for significantly reducing the occurrence of hip, non-vertebral, and vertebral fractures in the patient group concerned. Moreover, Boyoubei is the first biosimilar of Prolia (the original denosumab) that’s gained approval for global marketing.
Unlock exclusive market insights – purchase your research report now for a swift delivery!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13835
What regions are dominating the denosumab market growth?
North America was the largest region in the denosumab market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the denosumab market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Browse Through More Similar Reports By The Business Research Company:
Antifungals Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/antifungals-global-market-report
Antiobesity Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/antiobesity-global-market-report
Anemia And Other Blood Disorder Drugs Global Market Report 2024
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on:
